So what the heck is going on at Myogen today?
The company announced that ambrisentan met its primary goal of helping people increase the amount of exercise they could do, and doing so without hurting their livers. Two great data points. Good news right? Share price zooms right? Well good news but not good enough as MYOG spent the day heading to a three month low on the day they also reported a big BUT…but the drug failed to significantly increase the time to clinical worsening observed in that study population.
No comments:
Post a Comment